Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? Zacks - Wed Mar 1, 2023

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

ASRT : 0.8282 (+5.49%)
LYRA : 4.72 (-8.70%)
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates Zacks - Tue Feb 28, 2023

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYEL : 2.17 (-1.36%)
LYRA : 4.72 (-8.70%)
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates Zacks - Mon Feb 27, 2023

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TBPH : 9.12 (-0.22%)
LYRA : 4.72 (-8.70%)
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates Zacks - Tue Feb 21, 2023

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 28.57 (+12.08%)
LYRA : 4.72 (-8.70%)
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates Zacks - Thu Feb 16, 2023

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

SAGE : 13.69 (+0.81%)
LYRA : 4.72 (-8.70%)
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates Zacks - Tue Nov 8, 2022

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYRA : 4.72 (-8.70%)
GANX : 3.03 (-1.30%)
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Tue Sep 13, 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics), a clinical-stage therapeutics company leveraging its...

LYRA : 4.72 (-8.70%)
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting PR Newswire - Sat Sep 10, 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform...

LYRA : 4.72 (-8.70%)
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates Zacks - Tue Aug 9, 2022

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYRA : 4.72 (-8.70%)
PRPH : 4.71 (-4.85%)
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire - Tue Aug 9, 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)("Lyra" or the "Company"), a clinical-stage therapeutics company leveraging its proprietary XTreo™...

LYRA : 4.72 (-8.70%)

Barchart Exclusives

3 Highest-Yielding (And Safest) Dividend Aristocrats To Buy Today Barchart - Fri Apr 26, 6:30PM CDT
The highest-yielding dividend aristocrats aren't always the safest stocks to buy. Here's what I did to counteract this. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot